Clin2
NCT07517107Possibly a fitRecruiting

Blood tests to guide gastric cancer treatment decisions

Gastric Cancer

Part of Cancer, Digestive system clinical trials.

This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
600 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have gastric cancer (stomach or junction between stomach and esophagus) confirmed by biopsy or pathology
  • You are at least 18 years old and well enough to tolerate treatment (ECOG score 0–2)
  • Your blood counts, kidney, and liver function are adequate for cancer treatment
  • You are willing to provide regular blood samples for circulating tumor DNA testing
  • You fit one of three groups: planning neoadjuvant therapy before surgery, recovering after curative surgery, or have advanced/metastatic disease

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07076979Recruiting
Metabolic biomarkers for stomach cancer detection and monitoring

This study looks for metabolic markers in your blood and tumor tissue to help find stomach cancer early, predict your prognosis, and watch for recurrence. If you qualify, you would give blood and tumor samples for testing.

Shanghai
NCT05991947Recruiting
Blood test for early stomach cancer detection

This study is testing a new way to find stomach (gastric) cancer early using a simple blood test. It may help people who have just been diagnosed with stage I, II, or III stomach cancer and have not started treatment yet.

Hangzhou, Zhejiang
NCT04842916Recruiting
Study blood, tumor tissue, and preferences to predict stomach cancer response

This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.

Brest
NCT06893133Recruiting
DNA testing after gastric cancer surgery

This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.

Beijing, Beijing Municipality
NCT07508956Not yet recruiting· Phase 3
ctDNA-guided therapy after stomach cancer treatment

This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.

Shanghai, Shanghai Municipality
NCT07257380Not yet recruiting· Phase 2
ctDNA-guided therapy for advanced stomach cancer after neoadjuvant treatment

This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.

Shanghai, Shanghai Municipality

Hear when a new Gastric Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.